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Abstract: Drug delivery systems that are able to control the release of bioactive molecules and designed to 
carry drugs to target sites are of particular interest for tissue therapy. Moreover, systems comprising materials 
that can respond to environmental stimuli and promote self-assembly and higher order supramolecular 
organization are especially useful in the biomedical field. Suitable biomaterials for this purpose include 
elastin-like recombinamers (ELRs), a class of proteinaceous polymers bioinspired by natural elastin and designed using 
recombinant technologies. The self-assembly and thermoresponsive behaviour of these systems, along with their 
biodegradability, biocompatibility and well-defined composition as a result of their tailor-made design, make them 
particularly attractive for drug delivery. 
This review brings together information concerning ELR-based delivery systems that allow targeted delivery, especially 
ELR-drug recombinant fusion constructs, ELR-drug systems chemically bioconjugated in their monomeric and soluble 
forms, and drug encapsulation by nanoparticle-forming ELRs. Subsequently, we will focus on those drug carriers in which 
smart release is triggered by pH or temperature with a particular focus on cancer treatments in which both enhanced 
permeability retention (EPR) and local mild hyperthermia cause ELRs to become aggregated or form well-defined 
nanoparticles at the site of action. Systems for controlled drug release based on depots and hydrogels that act as both a 
support and reservoir in which drugs can be stored will be described, and their applications in drug delivery discussed. 
Finally, smart drug-delivery systems not based on ELRs, including those comprising proteins, synthetic polymers and 
non-polymeric systems, will also be briefly discussed. 
Keywords: Elastin-like Recombinamers, Drug delivery, Smart systems, Self-Assembly, Hydrogels, Nanocarriers. 
1. INTRODUCTION 
The next generation of biomaterials will require new 
components capable of undergoing bioresponsive self-
assembly and higher order supramolecular organization. In 
this sense, polymers that show lower critical solution 
temperature (LCST) phase-transition behaviour are a class of 
materials that can be used as fundamental pillars which are 
capable of interacting with biological systems at the 
molecular level [1]. 
A great variety of drug-delivery systems have been 
developed to obtain more efficient treatments and to deal 
with the largest possible number of diseases [2]. Recently, 
one of the main goals has been to develop systems that are 
capable of exhibiting a responsive behaviour to different 
environmental changes. Both polymeric and non-polymeric 
structures have been included in the wide variety of drug-
delivery systems designed, including micelles, liposomes, 
polymer-drug conjugates or inorganic nanoparticles, each 
with different benefits [3, 4]. 
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Advanced drug-delivery systems (DDSs) have been designed 
to transport pharmaceuticals to target tissues and to control 
drug release by responding to certain stimuli.  Thus, DDSs 
will improve therapeutic effects, reduce drug toxicity and 
improve the release profile with respect to the administration 
of free drugs, and in some cases can even penetrate into the 
targeted cells if required. Stimuli-responsive systems have 
become increasingly important in drug delivery due to their 
ability to rapidly respond to specific stimuli or to changes in 
their environment, including pH [5], temperature, ion 
concentration [6], light [7] and other changes [8]. Different 
materials, including natural or synthetic polymers, can be 
used to design such stimuli-responsive systems. Natural 
polymers such as proteins also exhibit several characteristic 
advantages when used as a biomaterial to form drug carriers 
as they are able to form nanostructures according to their 
established secondary, tertiary and quaternary structures. 
Secondary structures comprise those such as an α-helix or β-
sheet that can be used to bind micro- and nanostructures 
together [9, 10]. They have a versatile structure because of 
the broad range of design possibilities conferred by the high 
number of possible combinations of amino acids. In addition, 
proteins are made by living organisms and therefore have a 
higher likelihood of resembling natural tissues and being 
degraded by physiological pathways into the corresponding 
non-toxic byproducts. However, natural proteins vary from 
one batch to the next and can contain impurities, 
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reactions. Genetic engineering has overcome these 
disadvantages and has allowed the creation and improvement 
of new bioinspired protein-based polymers with enhanced 
structural and functional features with respect to their natural 
analogous. As such, these polymers are excellent candidates 
for the design of drug-delivery systems. Examples of 
genetically engineered well-developed drug carriers include 
protein polymers composed from elastin-like polypeptides 
due to their thermoresponsive behaviour and ability to 
coacervate. 
Elastin-like recombinamers (ELRs) are synthetic 
proteinaceous polymers bioinspired by natural elastin 
sequences and obtained using recombinant DNA techniques, 
thus allowing strict control of their amino acid composition 
and subsequent properties [11]. ELR genes are commonly 
expressed in Escherichia coli and purified by several heating 
and cooling cycles followed by centrifugation, in a process 
known as inverse temperature cycling (ITC). 
ELRs are based on the recurrence of short repeating peptide 
motifs present in tropoelastin; one of the most common 
repetitions is the pentapeptide sequence (Val-Pro-Gly-Xaa-
Gly), where Xaa is any amino acid except L-Proline. This 
type of polymer has a wide range of interesting properties, 
most of them derived from natural elastin, such as their 
biocompatibility, excellent mechanical properties, ability to 
self-assemble [12] and stimuli-responsive behaviour [13]. 
Moreover, these polymers are able to respond to different 
environmental stimuli, such as pH, ion concentration, 
pressure or temperature [8], with the latter being the most 
widely studied variable. The transition temperature (Tt) is 
the characteristic temperature below which the polymer 
chains remains hydrated, disordered and relatively extended, 
and above which the ELR chain folds hydrophobically and 
assembles to form a separate phase. In this state the chains 
adopt a dynamic secondary structure known as a β-spiral [12, 
14]. This Tt is controlled by intrinsic parameters, including 
composition, molecular weight and hydrophobicity, and it is 
also influenced by extrinsic factors such as concentration, 
solutes or pH. The tailor-made design of ELRs enables their 
transition temperature to be tuned and adapted for specific 
applications. 
ELRs have been used in a wide variety of applications in 
various biomedical fields such as drug delivery [15], tissue 
engineering [16], regenerative medicine [17, 18] and other 
medical devices [19]. The purpose of this review is to collect 
information about ELR-based delivery systems that promote 
target delivery, subsequently focusing on those drug carriers 
in which release is triggered by pH or temperature stimuli, 
especially depots and hydrogels that act as drug reservoirs 
and others not based on ELRs that have recently found uses 
as smart drug-delivery systems. 
Three different types of ELR constructs can be distinguished 
based on the different strategies used to design targeted 
drug-delivery systems. Firstly, ELR-drug recombinant fusion 
constructs, in which therapeutic sequences are fused to the 
backbone of the ELR in what is known as ELPylation. This 
system allows both expression and purification to be 
enhanced while improving drug delivery and 
pharmacokinetics [20]. The second type of targeted drug-
delivering ELRs consist of chemically bioconjugated 
recombinamers. In this case, modification is achieved by 
introduction of a “cross-linking” site in amino acid residues 
of the ELR in order to fuse a drug, thus allowing it to be 
delivered at the appropriate site and improving its 
pharmacokinetic properties (3). The final strategy described 
is based on drug encapsulation by ELR-based nanoparticles. 
A wide range of encapsulating ELRs have been studied, 
among which block copolymers that can form micelles by 
self-assembly in response to different parameters (27, 33A), 
chemically cross-linked microgel capsules and other systems 
used in gene delivery (37) can be highlighted. 
With respect to drug delivery triggered by temperature, the 
thermosensitive characteristics of ELRs make them one of 
the most interesting systems as regards a response to 
pathological changes in temperature. Hyperthermia, or local 
heating of the tumour site, is an excellent stimulus for the 
development of new anti-cancer therapies as a result of the 
vasodilatation [21], vascular permeability [22] and increased 
intracellular traffic into the tumour cells [23]. These effects 
may allow successful drug delivery by ELR-based systems 
as they are thermoresponsive and capable of changing from a 
soluble state to an insoluble structure with the formation of 
aggregates or self-assembly into well-defined nanoparticles 
at the disease site. Thus, these smart architecture features 
have been applied in the biomedical field specifically for 
drug-delivery purposes. Very little research has been devoted 
to the development of smart pH-sensitive ELRs, with recent 
proposals being related to ELR-based micelles with an 
ability to self-assemble and with pH-responsiveness [24] and 
pH-mediated drug delivery based on ELRs with an acid-
labile linker [25]. 
One of the suggestions for controlling the release of 
therapeutic agents and avoiding a fluctuating saw-tooth-like 
release is to apply a depot or hydrogel system that acts as a 
support and reservoir in which the drug can be stored [26]. 
The role of this system is to allow controlled delivery of the 
drug that can be tuned as a result of the different features 
derived from material design as well as polymer and drug 
concentrations, inter-solubility or matrix degradation 
simultaneous with drug release. 
Depot formation is governed by the smart behaviour and 
temperature sensitivity of ELRs; this, along with a tailor-
made structure designed to possess a Tt below the 
physiological temperature, makes them injectable systems. 
Thus, the ELR solution is injected at the site of action as a 
soluble ELR (unimers), and the polymers spontaneously 
coacervate to form the “drug depot” as a consequence of the 
temperature. In particular, regenerative medicine, 
neuroinflammation and cancer and diabetes therapy have 
benefited from this thermoresponsive behaviour [27]. 
Depending on the designed structure of the ELRs, a more 
organized polymeric network with a 3D structure can be 
obtained in hydrogels in which interchain connections can be 
provided by physical or chemical linkages. The 
interconnected 3D structure of the hydrogel, together with its 
ability to contain a large amount of water inside, provides a 
friendly environment for encapsulating therapeutic agents. 
Indeed, injectable hydrogels formed by in situ polymer 
crosslinking are of increasing interest for drug delivery as 
they enable a depot to be directly formed in vivo in the target 
tissue with just an injection and avoiding surgical 
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implantation [28-30]. Thus, direct application of the ELR at 
the target site helps to extend the local drug exposure time 
while minimizing systemic side effects [31]. Depending on 
the complexity of the ELR structure and the nature of the 
crosslinking, several different physical and chemical 
hydrogels will be described highlighting their different 
applications resulting from the specific bioactive molecule 
released. 
Finally, an overview of drug-delivery systems other than 
those based on ELRs will be provided. There are a wide 
variety of structures for drug-delivery systems made up of 
both polymeric and non-polymeric building blocks [32]. 
Some examples of natural proteins used in delivery systems, 
such as silk and collagen, will be described together with 
non-polymeric carriers defined by non-repetitive amino acid 
motifs with an ability to acquire tertiary or quaternary 
structures, including vault proteins [33] and viral proteins 
[34]. Subsequently, and staying with synthetic polymers, 
applications of poly(lactic-co-glycolic acid) (PLGA) in drug 
delivery will be reviewed [35], finishing with non-polymeric 
systems such as metal organic frameworks (MOFs) and their 
applications. 
2. TARGETED DRUG DELIVERY MEDIATED BY 
ELASTIN-LIKE RECOMBINAMERS 
Elastin-like recombinamers (ELRs) have been widely 
engineered to be suitable for application in targeted drug 
delivery without the need for any type of sensitivity to 
ensure drug release. Three different classes can be 
established based on the different strategies designed for this 
purpose, namely ELR-drug recombinant fusion constructs, 
ELR-drug combinations chemically bioconjugated in their 
monomeric and soluble form, and drug encapsulation by 
nanoparticle-forming ELRs. 
2.1. ELR-drug fusion constructs 
Recombinant DNA techniques have enormous potential for 
the construction of therapeutic proteins fused to an ELR 
backbone, which is often called ELPylation (for elastin-like 
polypeptide) [20]. This approach allows us to take advantage 
of a purification method that relies on the transition 
temperature described above, in which the recombinamer 
can be obtained pure after several heating and cooling cycles 
following by centrifugation, in a process called inverse 
temperature cycling (ITC). This system permits expression 
and purification to be enhanced while improving drug 
delivery and pharmacokinetics [36]. 
With this premise, an ELR was engineered fused to a poly-
aspartic acid tail (named ELR-D) with the aim of achieving 
self-assembled nanoparticles whose size is regulated by the 
charge repulsion of the aspartic acid tails. In order to add a 
biofunctionality to the nanoparticles formed, EGF 
(epidermal growth factor) was fused to the construct (to form 
the so-called ELR-D-EGF), being displayed on the surface 
of ELR-D. The binding of EGF to its receptor on the cell 
surface was assessed upon culture with A549 cells, a human 
lung adenocarcinoma epithelial cell line that overexpresses 
the EGF receptor, thereby confirming the expected increase 
in cell proliferation upon EGF binding when compared to the 
non-EGF-fused control. This system was also shown to be a 
good candidate for drug delivery applications by the loading 
of paclitaxel, a well-known anti-cancer drug, which showed 
a better internalization into A549 cellsinducing cell death 
[37]. 
In another study, a novel strategy involving fusion of a 
single-chain vascular endothelial growth factor (VEGF121)-
derived polypeptide to an elastin-like recombinamer was 
designed with the aim of enhancing the purification and in 
vivo stability of growth factors. This method was 
denominated as purification and delivery system (PADS) 
and the fusion product as VEGFPADS. The ELR-VEGF 
protein was successfully purified by ITC and evaluated in 
vitro in human umbilical vein cell (HUVEC) culture by 
means of vascular tube formation and cell proliferation and 
migration, showing results significantly comparable to free 
VEGF, thereby confirming the bioactive properties of the 
chimera and suggesting that the ELR tag has no effect on the 
binding of VEGF121 to its receptor. This approach also led to 
slower plasma clearance of the growth factor when injected 
in mice (half the rate for free VEGF121), although 
biodistribution was different for each one, with the former 
mainly being located in the liver and the free growth factor 
in the kidney. This work shows the potential of fusing 
growth factors to ELRs in order to lower the purification cost 
while maintaining their bioactivity [38]. 
Likewise, taking advantage of the ability of some ELRs to 
aggregate into coacervates when the temperature is raised 
above the transition temperature, a keratinocyte growth 
factor (KGF)-ELR chimera was recombinantly designed and 
bioproduced. Subsequent use of this material in vivo for the 
treatment of chronic wounds in diabetic mice led to 
enhancement of the granulation and re-epithelization of the 
wound when compared with the effect of KGF entrapped in 
fibrin gels due to the sustained administration of KGF in the 
ELR coacervate [39]. 
In order to improve the treatment of dry eyes, lacritin 
(Lacrt), a protein component of human tears with pro-
secretory activity in the lacrimal gland, was fused to an ELR 
comprising the VPGVG pentapeptide, thus allowing 
localization of the drug at the site of action due to 
precipitation of the recombinamer at physiological 
temperature, above the Tt, and overcoming the limitation of 
rapid tear turnover of single Lacrt when tested in vivo [40]. 
Another approach involving this same system combined the 
ability of a block copolymer (see following section 
concerning encapsulation systems) consisting of hydrophilic 
(serine-containing) and hydrophobic (isoleucine-containing) 
elastin-derived domains, thus being able to form 
nanoparticles at 37 °C, with the therapeutic properties of 
lacritin, which led to a faster regeneration of the corneal 
epithelium after wound induction in non-obese diabetic 
(NOD) mice when compared to an ELR-Lacrt that does not 
assemble into particles [41]. Similarly, the knob domain of 
the fibre capsid protein of adenovirus serotype 5, previously 
bound to an ELR and confirmed to improve internalization 
into hepatocytes [42], which was shown to bind to the 
coxsackievirus and adenovirus receptor highly expressed in 
the lacrimal gland, was fused to the latter ELR-Lacrt 
nanoparticle, thus allowing selective transcytosis of the 
ELR-drug fusion into the cells of this gland [43]. 
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The recombinant fusion of anti-inflammatory proteins, such 
as antibodies that recognize pro-inflammatory cytokines, has 
also been achieved using the above-mentioned ELPylation 
approach. Due to the limitations of prokaryotic recombinant 
expression systems regarding post-translational 
modifications that most of these anti-inflammatory proteins 
undergo, many of them have been expressed in plants. Some 
of the first studies performed in this bioproduction system 
were aimed at evaluating the expression and purification of 
different proteins fused to ELRs in tobacco leaves, with 
satisfactory results [44, 45]. With regard to antibodies, anti-
human TNF was also fused to an ELR, produced in 
Nicotiana tabacum and purified by ITC. Further 
investigation was performed both in vitro and in vivo and 
showed both similar bioactivity to free TNF and an increase 
from 28 minutes to 11 hours (24-fold) in terms of serum 
half-life and clearance, thus indicating an improvement in 
the pharmacokinetics of the antibody [46]. Similarly, IL-10 
[47] and an HIV-neutralizing antibody [48] were also 
engineered into an ELR-bound DNA vector for expression in 
tobacco plants, showing analogous bioactivity to that of the 
free proteins without the need for cleavage from the ELR 
tag. Nevertheless, the use of peptides instead of whole 
proteins for fusion to ELRs allows the expression in more 
common systems such as E. coli, thereby reducing costs and 
usually performing better in terms of yields. As an example, 
six repetitions of the peptide AP1, a ligand for IL-4 receptors 
(IL-4Rs), were genetically bound to a VPGVG-based ELR. 
The resulting chimeric recombinamer was fluorescently 
labelled and found to bind to IL-4Rs in vitro in different 
tumour cell lines in which IL-4Rs are highly expressed, thus 
leading to an amplification of the expression of some anti-
apoptotic proteins and preventing drug-induced cell death. 
The system tested also resulted in tumour accumulation in 
vivo, with this effect being evident as early as 10 minutes 
post-injection of the ELR-AP1, peaking at 6 h and being 
maintained up to 24 h [49]. This carrier should therefore be 
tested as an actual drug-delivery system with a 
chemotherapeutic agent. 
Alternatively, self-assembled ELRs have been designed as 
nanovaccines against tuberculosis by the recombinant fusion 
of an antigen from Mycobacterium tuberculosis. In this case, 
a nanoparticle-forming di-block consisting of a glutamic acid 
(E) hydrophilic block and an isoleucine (I) hydrophobic one, 
with different amino acids as guest residues, was chosen. 
The resulting particles were found to be monodisperse and 
stable despite fusion to the antigen, and additional work was 
performed in order to assess the ability of the nanovaccine to 
elicit an immune response in vivo, thus resulting in the 
triggering of an innate response following by the presence of 
IL-5 and IgM and IgG, which clearly suggests an adaptive 
Th2 response. Meanwhile, the ELR itself did not have any 
immunomodulatory effect. In conclusion, these results 
suggest the potential application of ELRs as antigen carriers 
[50]. 
2.2. Chemically bioconjugated ELR-drug constructs 
Covalent bioconjugation has been extensively used to 
achieve therapeutic elastin-like recombinamers chemically 
fused to drugs, thus allowing an improvement in the 
solubility of hydrophobic drugs and in the pharmacokinetics 
of these drugs. This covalent binding is performed by 
introducing cross-linking sites via the modification of 
reactive groups in the side chains of different amino acids, 
such as thiol groups in cysteine or the ε-amino group in 
lysine residues. In contrast to the recombinant fusion, this 
approach implies that non-protein drugs can be 
bioconjugated. 
Doxorubicin (Dox), a widely used chemotherapeutic agent, 
has been bioconjugated to several ELRs. One of the first 
studies in this regard accomplished such conjugation by 
modifying the amine groups present in lysine residues of the 
ELR to obtain a free maleimide group, which reacted with a 
Dox-hydrazone complex containing an acid-labile hydrazine 
bond to achieve bioconjugation. Further in vitro studies 
performed to assess the cytotoxicity and subcellular 
localization of the ELR-Dox showed a similar level of 
squamous cell carcinoma (FaDu) cell death (less than 10% 
of survival after 72 h) when compared to the free drug, 
although different localizations were observed, with ELR-
Dox being dispersed throughout the cytoplasm and free 
doxorubicin mostly internalized in the nucleus, suggesting 
different cell-death pathways in each case [51]. Another 
possibility involving chemical conjugation via cysteine 
residues was evaluated and an ELR-Dox drug system 
synthesized, this system allowing intracellular release of the 
drug as a result of an acid-labile hydrazine bond [52]. An 
alternative approach using the latter recombinamer involved 
the inclusion of a GFLG tetrapeptide linker that is 
recognized by lysosomal cathepsin proteases, thus permitting 
the release of the drug after endocytosis. A Tat domain, 
which is a cell-penetrating peptide (CPP) derived from the 
trans-activating protein found in HIV-1, was also fused to 
this recombinamer, theoretically improving cellular uptake 
of the conjugated drug. In vitro studies were performed with 
both non- and Dox-resistant carcinoma cell lines, resulting in 
a higher cytotoxicity towards drug-resistant cells in the case 
of the ELR-Dox when compared to the drug itself (1.4% and 
31.9% resistance, respectively, in the case of breast cancer 
cells) [53]. Additionally, a nanoparticle-forming block 
copolymer ELR was used to conjugate doxorubicin via 
cysteine residues. Hence, 40nm particles were achieved 
above the Tt of the ELR, with little effect of Dox on this 
feature and the drug being located at the core of the 
nanoparticle. Tumour regression was observed in in vivo 
assays using a mouse colon cancer model after a single dose, 
which represents a great advantage with respect to the free 
drug [54]. Furthermore, other chemotherapeutic drugs, such 
as paclitaxel, have been bioconjugated and found to present 
the same benefits as Dox in terms of pharmacokinetics and 
improved solubility [55]. 
As an example of a likely ELR as a drug carrier for maternal 
delivery and prevention of foetal exposure, an ELR-
fluorescent probe system was designed in order to 
demonstrate the potential of this class of polypeptides for use 
in such applications, starting from the hypothesis of the 
lower ability of these proteins to cross the placental barrier 
compared to free drugs. The covalent binding of a 
fluorescent dye to an ELR or a SynB1-ELR backbone, with 
SynB1 being another CPP, allowed traceability when 
injected intravenously into a pregnant rat model. The ex vivo 
fluorescent measurement of the placenta and the foetus 
showed that very small quantities of the labelled ELR 
crossed the placenta, whereas the observation of different 
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maternal organs showed a preferential accumulation of the 
ELR in kidneys, liver and the placenta itself, thereby 
suggesting the potential of elastin-like recombinamers as 
safe drug carriers for different diseases, such as preeclampsia 
[56]. 
2.3. Elastin-like recombinamers as non-responsive 
encapsulation systems 
The aforementioned recombinant nature of ELRs permits a 
strict control over their physical and chemical properties, 
thus allowing the tailoring of their self-assembly into 
different structures, such as different types of nanoparticles, 
depending on the amino acid present as guest residue in the 
VPGXG pentapeptide. One of the most widely explored 
possibilities is the construction of ELRs consisting of 
hydrophobic and hydrophilic blocks, known as “block 
copolymers”. The design of a di-block recombinamer 
implies that it undergoes a conformational change from an 
extended form to micelles above the Tt of the hydrophobic 
part [57, 58]. In this case, the Tt is called the critical micelle 
temperature (CMT) and can be controlled by varying the 
length and composition of the hydrophobic block, while the 
size of the micelle depends mostly on the length of the ELR 
and the hydrophilic-to-hydrophobic block ratio. The core of 
the micelle is suggested to be occupied by the hydrophobic 
block, while the hydrophilic one is oriented towards the 
corona, in contact with the surrounding water molecules. 
Further investigation regarding the self-assembly behaviour 
of ELRs into micelles or hollow vesicles (see ¡Error! No se 
encuentra el origen de la referencia.) involved changing the 
arrangement and length of the constituent blocks, leading to 
the conclusion that these two different structures can be 
obtained using ELRs comprising glutamic acid- and alanine-
based blocks, thereby suggesting the potential 
functionalization of these recombinamers for subsequent 
applications [59]. Additionally, the effect of surfactants [60] 
and different salts [61] on ELR self-assembly was assessed 
and it was found that these conditions can completely 
modify the structure of the self-assembled ELRs, i.e. the 
formation of micelles or vesicles, depending on the 
concentration of these additives in the aqueous 
recombinamer solution. 
Figure 1. TEM images of self-assembled nanoparticles 
stained with 1% uranyl acetate of the ELR enriched with 
glutamic and alanine. Micelle like (A) and vesicle like self-
assembled ELR architecture (B) [59]. 
With the purpose of exploring the possibility of adding novel 
bioactivities to ELRs in order to enhance their drug-delivery 
features, Plasmodium falciparum FK506-binding protein 
(FKBP), which binds to the chemotherapeutic anti-
proliferative drug rapamycin, was fused to the hydrophilic 
part of a di-block micelle-forming recombinamer. This 
modification increased the affinity of the ELR for this drug 
since FKBP is exposed in the corona of the nanoparticle. In  
vitro studies in a breast cancer cell line showed an increase 
in the loading capacity of the drug by the particles and its 
release, therefore improving its activity towards these 
tumour cells [62]. 
Chemical cross-linking can be used as another method for 
the development of thermo-responsive microgel capsules 
(MCs) with potential applications in drug delivery. This 
approach permits shape-stable microspheres, the pore size of 
which can be reversibly tuned by increasing or lowering the 
temperature, thereby modifying the permeability to drugs, to 
be obtained. In a first example of this technology, a mixture 
of ELR and albumin at different ratios was cross-linked, with 
the resulting system showing shape stability and changes in 
the surface structure of the MCs depending on whether the 
temperature was above or below the Tt. In the first case, the 
release of BSA and prednisone acetate, both used as model 
drugs, was faster than in the latter. Optimal release was 
found in the temperature range 20-40 °C [63]. ELR/BSA 
MCs were subsequently produced by a two-step cross-
linking method. The ability of these microcapsules to release 
a drug was evaluated using two similar fluorophores, namely 
rhodamine B (red) and FITC (green), this latter possessing a 
negative charge, thus showing a charge-independent release 
of both molecules from the MCs. Similarly to the previous 
work, release of the cargo molecules was faster when the 
temperature was raised above Tt, and vice versa [64]. 
Dual microparticles consisting of two different biomaterials, 
namely ELR-chitosan or alginate-chitosan, have also been 
designed as a proof-of-concept methodology following a 
layer-by-layer approach and found to have potential as drug-
delivery systems [65]. Further studies with the ELR-chitosan 
microparticles involved recombinant functionalization of the 
ELR with the RGD cell-adhesion sequence for integrins. 
These particles, with a size of 3-4 μm, were loaded with 
fluorescently labelled DQ-ovoalbumin as a model protein 
and used to supplement the medium in human mesenchymal 
stem cells (hMSCs) culture for 72 h. The findings of this 
study showed them to be non-cytotoxic, with improved 
internalization of the protein to the cytoplasm than in the 
case of the non-functionalized (non-RGD) ELR-chitosan 
microparticles, as evidenced by DQ-ovoalbumin 
degradation, which results in a shift in fluorescence 
emission. Thus, this strategy suggests the utilization of 
microparticles formed by different biocompatible 
macromolecules as carriers for drug delivery [66]. 
In a more recent work, elastin-like-silica hybrid micelles 
were obtained by fusing the silaffin R5 peptide to an ELR. 
Silaffins are polycationic peptides with affinity for silica 
found in Cylindrotheca fusiformis, playing a role in the 
formation of its silica cell walls. However, on their own 
these peptides self-assemble into uncontrolled structures, 
thus leading to a silicification process resulting in a network 
of fused silica nanoparticles. The fusion of this peptide to an 
ELR capable of self-assembling into micelles permits the 
synthesis of uniform hybrid ELR and silica nanoparticles 
that could be used as drug-delivery systems, as shown by the 
higher monodispersity and larger silica-coated micelles of 
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the silaffin-containing recombinamer when compared with 
the micelle-forming non-silaffin counterpart [67]. 
The same group that engineered the ELR-D-EGF fusion 
protein discussed above designed another approach for 
loading of the previously described single-chain vascular 
endothelial growth factor (scVEGF121)-derived polypeptide 
into nanoparticles. This approach takes advantage of the non-
covalent interaction between coiled-coil leucine zipper 
domains, one with acid (helix A) and another one with basic 
(helix B) residues, both peptides being designed to form 
stable, parallel, coiled-coil heterodimers (Figure 2). An 
ELR-D-helixB and a helixA-scVEGF121 were designed and 
recombinantly produced in E. coli and found to form coiled-
coil nanoparticles. Further experiments involving the loading 
of paclitaxel into the nanoparticles showed the enhanced 
cytotoxicity of the resulting drug-delivery system upon 
supplementing the medium with these particles in the culture 
of HeLa cells. This study showed uptake of these particles 
by the cells and the release of paclitaxel specifically via the 
VEGF receptor [68]. 
Figure 2. Schematic representation of the tethering of the 
growth factor to nanoparticles through the formation of 
coiled-coil assemblies. Reprinted with permission from 
Assal et al. [68]. 
Other novel encapsulation systems have been designed 
recently taking advantage of the properties of other 
recombinamers resulting from combination of the VPGAVG 
hexapeptide, also found in human elastin, and VPGVG 
sequences, together with crosslinking regions that permit 
further modification of the ELR. This ELR was found to 
form microparticles (11 ± 5µm) via a water-in-oil emulsion, 
which were combined with and covalently attached to super-
paramagnetic iron oxide nanoparticles with the aim of 
applying a controlled magnetic field once implanted in vivo 
and improving the targeting and tracking of these vectors 
when loaded with a drug. To assess the actual potential of 
these microparticles, they were loaded with either 
fluorescently labelled bovine serum albumin (BSA) as a 
model drug or neural growth factor (NGF) for in vitro 
release studies. In the latter study, a neural differentiation of 
the PC12 cell line was also observed. However, this study 
was quite limited and some improvements are still required, 
especially a reduction in particle size in order to be suitable 
for in vivo applications [69]. 
Various studies have also been performed with ELRs as 
gene-delivery systems, with all of them relying on the 
electrostatic interactions between negatively charged DNA 
molecules and positively charged ELRs due to substitution 
of the guest amino acid in the VPGXG pentapeptide by an 
amine-containing residue, such as lysine, or the fusion of a 
tail including positively charged amino acids. The latter 
approach has been used to attach an oligolysine tail (K8) to 
the ELR to give the so-called K8-ELR, which was 
subsequently incubated with plasmid DNA (pDNA) 
including the gene encoding for green fluorescent protein 
(GFP) and found to exhibit good complexation and stability 
of the polyplexes. The transfection efficiency was also 
assessed by way of culture with in vitro MCF-7 breast cancer 
cells, with fluorescence due to GFP expression being 
observed. However, some cytotoxic effects were also 
observed, probably due to the K8 tail [70]. In another recent 
work, a positively charged ELR was fused to the penetratin 
cell-penetrating peptide and the LAEL fusogenic peptide. 
Stable polyplexes of around 200 nm, with a zeta-potential of 
+24 mV were formed and found to be optimal for the desired 
application. Haemocompatibility and cytotoxicity assays 
showed the innocuous nature of these ELRs. Furthermore, 
the LAEL-containing ELR was found to be the best choice in 
terms of cellular uptake and transfection among the ELRs 
tested. These results show the potential of highly 
biocompatible ELRs for gene-therapy applications [71]. 
3. DRUG DELIVERY TRIGGERED BY ELR SMART 
BEHAVIOUR 
As stated above, soluble ELRs suffer a reversible phase 
transition in response to changes in temperature which, 
depending on their architecture, causes them to aggregate or 
self-assemble into well-defined nanoparticles. As a result, 
these smart architectural features have been applied in the 
biomedical field, especially for drug-delivery purposes. 
3.1. Drug delivery triggered by temperature: 
hyperthermia and cancer therapy 
3.1.1. ELR aggregates 
The use of drug delivery systems for cancer treatment is 
dependent on the enhanced permeability and retention (EPR) 
effect present in tumour tissues. The EPR effect is 
characterized by the accumulation of macromolecules and 
lipids as a consequence of restricted lymphatic drainage. The 
regional blood flow to the tumour, the permeability of the 
tumour vasculature, the structural barriers imposed by 
perivascular tumour cells and extracellular matrix, together 
with intratumoural pressure, must all be taken into account in 
the design of novel drug-delivery agents [72]. The 
combination of an EPR with local mild hyperthermia (40-44 
°C) [73] makes these constructs appropriate candidate 
biomaterials for cancer treatment. 
The design of ELRs with a Tt similar to that found under 
conditions of mild hyperthermia opens the way to this 
application as, when local hyperthermia is applied, the ELR 
changes its soluble state to an insoluble one. The ELR 
therefore aggregates under local mild hyperthermia at the 
site of action and can be used for cancer therapy. This 
aggregation increases its accumulation and time of action. 
Tumour accumulation may be due to the passive trafficking 
of the ELR due to the EPR effect [27], the increased tumour 
blood flow and vascular permeability as a consequence of 
hyperthermia [74], or due to the aggregation itself, which 
localizes more ELR in the tumour region [75, 76]. Studies 
with a 14C-labeled ELR ([14C] ELP1) allowed the 
degradation rate and accumulation in the tumour to be 
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studied [75]. The in vitro degradation rate upon exposure to 
murine serum was 2.49 wt.%/day, with similar levels being 
obtained after intravenous injection into nude mice 
(2.46 wt.%/day), with a terminal half-life of nearly 9 hours. 
These data showed a 1.8-fold increase in accumulation for 
heated tumours when compared with controls. Another study 
investigated the enhanced accumulation of ELRs at the 
tumour site due to their thermosensitive behaviour [76]. 
Consecutive heating cycles were applied to the tumour, 
resulting in the formation of adherent ELR microparticles in 
the tumour vasculature in each thermal cycle. In contrast, 
when the heat was turned off the particles were dissolved, 
thereby creating a transvascular concentration gradient 
which pushed the ELR into the tumour space. Aggregate 
accumulation was monitored by labelling the ELR with 
fluorescent reporter molecules. This study resulted in a new 
methodology known as “tumour thermal cycling”, which 
could potentially be used for targeted delivery to solid 
tumours. 
At a cellular level, the ELR transition can be used to increase 
cellular uptake of the ELR-drug complex, thus triggering 
higher delivery levels of the drug. In order to achieve better 
results, short functional motifs known as cell-penetrating 
peptides (CPPs), such as penetratin, Bac, TAT and SynB1, 
were used. These CPPs have been shown to efficiently 
internalize various molecular loads in order to target the 
inside of eukaryotic cells [77-79]. Thus, Raucher’s lab 
developed a thermally responsive ELR with the CPPs 
penetratin (pen), Tat or Bac fused to the inhibitor  c-Myc 
(H1), which is known to inhibit proliferation in MCF-7 
breast cancer cells [80]. The intracellular distribution of the 
resulting ELR-H1 fused with the different CPPs was 
evaluated. Bac-ELP-H1 was found to be localized in the 
nucleus and was the most potent inhibitor of MCF-7 cell 
proliferation at day 7. In contrast, the Pen- and Tat-modified 
ELRs were localized in the cytoplasm. As a result, Pen-ELP-
H1, which decreases the proliferation rate in MCF-7, had no 
effect on proliferation up to 11 days of treatment. This study 
combined the advantages of thermal targeting and delivery 
of a therapeutic peptide such as c-Myc, thus making this 
system an improvement on previous studies. Further in vivo 
research using an orthotopic model of breast cancer in 
C57BL/6 mice to test the ability of the Bac-ELR-H1 
construct to target and reduce tumour growth was developed 
[81]. Treatment involving daily injections of Bac-ELR-H1 
during 7 days over a total of 2 weeks, in combination with 
hyperthermia, reduced the progression of breast tumours by 
nearly 70%. In treated mice the ELR was able to target the 
site of the solid tumour, escape from the vasculature, enter 
the tumour cells and inhibit their proliferation. Similar 
results were obtained with the same Bac-ELR-H1 construct 
but this time with glioblastoma in a rat glioma model [82]. 
An 80% reduction in tumour volume was observed, with 
complete regression in 80% of animals, when combined with 
hyperthermia. As a result, tumour-related neurological 
deficits were delayed and the median survival time doubled. 
Additionally, a Bac peptide fused to an ELR was also used 
by the same group in further studies. Thus, addition of a Bac 
peptide at the N-terminus and an amino acid fragment from a 
peptide derived from p21 at the C-terminus led to the 
construct Bac-ELR-p21 [83]. Under mild hyperthermia 
conditions, the selected ELR showed a decrease in the 
proliferation of SKOV-3 cells in comparison with the 
thermally unresponsive control. This increase in the anti-
proliferation effect was due to the action of p21, which was 
located in the nucleus for those cells incubated under 
hyperthermia. Another polypeptide was designed using the 
same ELR structure but with the CPP SynB1 at the N-
terminus and the therapeutic peptide GRG at the C-terminus 
(SynB1-ELR-GRG) [84]. GRG was designed to interfere 
with UsnRNP biogenesis by competing for methylation with 
Sm proteins. In vitro assays in HeLa cells showed the 
localization of the polymer in the cytoplasm. Cellular uptake, 
proliferation and apoptosis effects derived from the 
therapeutic GRG peptide were therefore increased by 
hyperthermia treatment. 
Similarly, a targeted CPP-ELR has been used in combination 
with hyperthermia to deliver small molecule drugs such as 
doxorubicin [85] or paclitaxel [86]. Thus, doxorubicin was 
conjugated to the Tat-ELR via a cathepsin-cleavable GFLG 
spacer to form the construct Tat-ELR-GFLG-Dox as 
explained above. In a subsequent study [85], the cytotoxic 
effects of the drug increased 20-fold when the ELR 
aggregated as a result of the application of mild 
hyperthermia. Paclixatel, in turn, was linked to a SynB1-
ELR via an acid-cleavable hydrazone linker [86], being 
SynB1 a CPP that is known to internalize via endocytosis. 
The hydrazone linker is cleaved at the acidic pH found in 
lysosomes and endosomes, thereby triggering the 
intracellular release of paclixatel. In this study the delivery 
of paclixatel was achieved under hyperthermia, and 
inhibition of proliferation and apoptosis induction was 
confirmed using MCF-7 breast cancer cells and found to be 
comparable with the effects of the free drug. 
3.1.2. Self-assembled ELR particles 
In addition to thermosensitive ELR constructs that aggregate, 
even reaching depot status, self-assembled ELR-based 
architectures are also attractive for the biomedical field. In 
this sense ELRs are usually designed as block copolymers 
comprising a hydrophilic and a hydrophobic part being able 
to self-assemble, thus leading to the formation of well-
defined nano-sized particles. When the polymer is 
solubilized in aqueous solution and is heated above its Tt, 
the ELR chains orientate in a way that triggers the formation 
of core-corona structures, with the corona comprising 
hydrophilic blocks and core hydrophobic blocks. The micelle 
or hollow vesicle shape resulting after self-assembly can be 
changed by varying the ELR block arrangement and length 
[59]. Studies with different ELR constructs containing 
glutamic acid and alanine blocks confirmed this possibility, 
thereby highlighting the high versatility of ELR-based 
diblocks. ELR diblocks in which the hydrophobic part 
possesses a Tt > 42 °C under local mild-hyperthermia 
conditions have been widely studied due to their potential 
use in cancer therapy [87]. 
Self-assembled ELR nanoparticles can acquire different 
functionalities upon the incorporation of recognition motifs 
such as RGD, NGR or Fn3 peptides in the hydrophilic block. 
The RGD peptide acts by increasing the avidity of the 
copolymer for its ligand (αIIB integrin in activated platelets 
and the αvβ3 integrin in healthy angiogenic tissue in addition 
to tumour vasculature) while maintaining its Tt and ability to 
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self-assemble, thereby constituting a thermally tunable 
switch for the ELR in K562 leukaemia cells [88]. NGR is 
known to bind to CD13 isoforms expressed in tumour 
vessels and has been widely used for tumour targeting. This 
peptide was bound to ELR diblocks in a series of constructs 
with different hydrophilic-to-hydrophobic ratios [89]. At 
ratios of between 1:2 and 2:1, monodisperse spherical 
micelles were found with the peptide pointing outwards. In 
addition, the critical micelle temperature (CMT) could be 
controlled by varying the length of the lower Tt block. This 
study was the first demonstration of temperature-triggered 
multivalency in which ELR diblocks with a functional 
peptide maintain their ability to self-assemble and target 
tumour cells, with self-assembly into micelles enhancing the 
local density of the functional peptide on the corona. 
The fibronectin type III domain (Fn3), which binds the 
integrin αvβ3, has also been fused to ELR diblocks [90]. The 
self-assembly behaviour of the resulting constructs was 
studied through the bioproduction of ELRs with different 
hydrophilic and hydrophobic block lengths. The result was 
an increase in the uptake of ELR with Fn3 in comparison 
with the unimers in a transfected human leukaemia cell line 
overexpressing the integrin αvβ3 (K562/αvβ3). In a later 
study, a qualitative breakthrough in the design of ELR 
diblocks fused to functional peptides was accomplished. 
Thus, Chilkoti’s group constructed an ELR-based drug 
carrier termed nanopeptifier, that was able to improve 
cellular uptake by controlled exposure of CPPs, which 
toggled in response to the application of external mild 
hyperthermia (Figure 3) [91]. The construct (Arg8-ELRBC-
cBH3) was genetically engineered to possess a CPP (Arg8) 
at the N-terminus and the therapeutic payload peptide cBH3 
(derived from the proapoptotic Bak protein) located at the C-
terminus. The therapeutic cBH3 peptide was separated by an 
RVRR peptide linker cleavable by furin and cathepsin B 
proteases. The nanopeptifiers are soluble at physiological 
temperature (37 °C), whereas under of mild hyperthermia 
conditions (42 °C) they self-assemble into spherical micelles 
displaying a high density of CPP on their corona and with 
cBH3 located in the micelle core. Although some uptake of 
the nanopeptifier occurs at 37 °C, when the temperature is 
increased to 42 °C this cell uptake increases dramatically. 
Once the complex is internalized, the action of either furin 
(localized in the trans-Golgi) or cathepsin B (early and late 
endosomes and lysosomes) favours release of the cBH3 load. 
Increases of up to 130 arbitrary cell fluorescence units were 
found to induce the therapeutic effect of cBH3. Its 
therapeutic action was assessed by activation of caspase-3, 
which is involved in apoptotic processes. Thus, the 
nanopeptifier was able to create a cytotoxic switch that 
induces apoptosis only when it is in the micelle 
conformation. 
In addition to ELRs genetically designed as block 
copolymers, a series of smart ELR-PEG block constructs 
have been synthesized chemically [92]. The specific strain 
promoted alkyne-azide cycloaddition (SPAAC) reaction was 
used to build the copolymer. Constructs with different ELR 
and PEG lengths were accomplished by varying their 
architecture (linear or miktoarm). The result was 
conservation of the thermosensitive nature of the ELR, 
which promoted self-assembly into micelles. The ability of 
these constructs to encapsulate a hydrophobic fluorescence  
Figure 3. Design and function of an ELR diblock 
nanopeptifier. (A) Each nanopeptifier is formed by a 
therapeutic payload, an ELR diblock and a CPP. (B) At 
physiological temperature (37 ºC) “off state”, nanopeptifiers 
are soluble displaying a single CPP on their hydrophilic 
terminus. At mild hyperthermia conditions (42 ºC) “on state” 
the nanopeptifiers self-assemble into spherical micelles, 
displaying a high density of CPPs on the micelle corona. The 
increases CPP density amplifies the cellular uptake [91]. 
dye was shown, thereby demonstrating the potential of these 
ELR-PEG hybrid copolymers for the encapsulation of 
hydrophobic drugs. 
The above examples reflect the potential of ELRs as 
thermoresponsive materials, which are of growing interest in 
the biomedical field. Their recombinant nature, which allows 
a total control of their architecture, and their self-assembly 
properties open the way to new features such as thermal 
switching, which can even be used to direct cellular uptake. 
All these studies involve new applications in diseases such 
as cancer and are therefore a promising field for ELR-based 
biomaterials. 
3.2. Drug-delivery systems based on pH-sensitive ELRs 
pH-Sensitive drug-delivery systems have received increasing 
interest in recent years as pH plays an important role in 
many biological process and some diseases such as asthma, 
peptic ulcer, heart disorders, hypertension and cancer [93]. 
For example, the pH found in healthy tissue or in the blood 
is different to that found in tumours due to tumour hypoxia 
and the production of substances such as lactic acid resulting 
from anaerobic metabolism and ion channel changes [94, 
95]. 
Given these differences in pH between normal tissue and the 
tumour microenvironment, Callahan et al. proposed the first 
pH-sensitive ELR-based polypeptide micelle that 
disassembles at the lower pH found in solid tumours. Based 
on previous work in which these authors demonstrated that 
ELR block copolymers with different lower critical solution 
temperatures (LCSTs) are able to form micelles over a 
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specific temperature range [89], ELRBCs containing 
histidine-rich hydrophobic blocks were designed with the 
aim of creating pH-sensitive nanoparticles that self-assemble 
at pH 7.4 and disassemble at pH 6.4 [24, 96]. Thus, they 
synthesized two different ELRBCs, containing a combination 
of hydrophobic (pH-insensitive block, to form the corona of 
the micelles) and hydrophilic blocks (pH-sensitive blocks, to 
form the core of the micelles). [VG7A8]-80/[VH4]-100 was 
selected as it was found to be the only ELRBC that formed 
stable nanoparticles at 37 °C. A pH-insensitive ELR 
[VG7A8]-64/[V]-120 was selected as negative control in 
order to verify the ability of the pH-sensitive micelle formed 
by [VG7A8]-80/[VH4]-100 to respond to changes in pH. 
The ELRBCs were examined in nude mice bearing HCT-15 
human colon adenocarcinoma xerographs. Both polymers 
maintain the beneficial behaviour of high MW drug-delivery 
nanoparticles, with [VG7A8]-80/[VH4]-100 presenting a 
lower accumulation in healthy tissues and greater affinity for 
the lower pH of the tumour environment. It was found that 
[VG7A8]-80/[VH4]-100 shows a more homogeneous spatial 
distribution and greater penetration within the tumour tissue 
compared to pH-insensitive ELRBC micelles based on 
[VG7A8]-64/[V]-120. The histidine-rich ELRBC micelles are 
able to undergo a pH-triggered disassembly that means the 
individual polymer chains increase their diffusion capacity 
and can penetrate inside the tumour. However, pH-
insensitive micelles tend to accumulate around the tumour 
space as they cannot respond to lower pH, and cannot 
therefore undergo pH-dependent disassembly, thus meaning 
that the rate of accumulation in the extravascular space 
increases. This new pH-responsive mechanism suggests the 
potential utility of this system for improving drug delivery 
to, or the imaging of, solid tumours. 
Another strategy is based on the design of a different 
structure in which pH-dependent delivery is related to pH-
labile amino acid sequences. In order to improve the results 
obtained by MacKay et al. in a previously reported study 
[54], a new strategy was proposed by Hu et al. Thus, these 
authors reported the first ELR genetically fused to a tumour 
homing peptide, F3, fused to the same structure proposed 
previously by MacKay et al. and also carrying a cysteine-
rich fragment (Gly-Gly-Cys)8 (C8) with the aim of creating a 
bioactive and well-defined polypeptide F3-ELP-C8, which 
was conjugated with doxorubicin (DOX). F3 is a 31-amino 
acid sequence that specifically attaches to nucleolin, which is 
present on the surface of activated lymphocytes, angiogenic 
endothelial cells and many tumour cells [97, 98]. The C8 
segment was selected to bind multiple DOX molecules to the 
Cys residues of the F3-ELR-C8 via an acid-labile hydrazine 
linker (3-maleimide propionic acid hydrazine (BMPH)) to 
form F3-ELR-C8-DOX (Figure 4). They demonstrated that 
DOX has a faster delivery at lower pH (5.0) than at pH 7.4 
(physiological pH), where most of the DOX molecules are 
attached to the conjugate. This result reveals that the 
hydrazone bond is stable at the pH of blood and healthy 
tissues but breaks at lower pH. The pH-dependent release of 
DOX from the conjugates suggests endolysosomal drug 
delivery once the nanoparticles have been taken up by the 
cells, which is related to the pH-responsive behaviour. 
In vitro studies demonstrated that F3-ELR-C8-DOX 
nanoparticles bound to the cell surface earlier and exhibited 
more drug accumulation in the cell cytoplasm and nucleus 
than ELR-C8-DOX, thereby demonstrating the important 
role that F3 plays in the cell interaction. This result was 
confirmed by way of in vivo experiments in mice with a C26 
tumour model, in which F3-ELR-C8-DOX was found to 
have a longer half-life than free DOX and ELR-C8-DOX, a 
lower accumulation in cardiomyocytes and did not cause 
histological damage in heart tissue. This is an important 
point due to the fact that cardiocytotoxicity is often the worst 
side effect of DOX use. With regard to its efficiency in 
reducing the tumour volume, the results obtained thirteen 
days after treatment demonstrated that it exhibits better 
antitumour efficacy and increased animal survival compared 
with the control ELR-C8-DOX. Furthermore, histological 
analyses showed a higher apoptotic effect, which is related to 
the pH-sensitivity and local tumour distribution of the 
nanoparticles around the tumour cells [25]. 
Figure 4. Schematic representation of the synthesis of F3-
ELR-C8-DOX nanoparticles, showing (A) the synthesis-
conjugation of F3-ELR-C8-DOX and (B) the molecular 
structure of this drug delivery system. Adapted with 
permission from Hu et al. [25]. 
4. THERAPEUTIC ELR DEPOTS AND HYDROGELS 
The smart behaviour and temperature sensitivity of ELRs 
can be exploited in such a way as to control their aggregation 
both in vitro and in vivo, thus paving the way to advanced 
medical applications such as drug depot formation for tissue 
regeneration, neuroinflammation, cancer and diabetes. 
As a general rule of thumb, these ELRs have been designed 
to possess a Tt below the physiological temperature of 37°C. 
The ELRs are solubilized and injected at the desired site of 
action as soluble ELRs (unimers), where they immediately 
coacervate and form the depot as a result of the temperature. 
Thus, the direct application of ELRs at the target site helps to 
extend local drug exposure time while minimizing systemic 
side effects [31]. 
As stated above, one of the main applications for ELR 
depots is in regenerative medicine. Thus, research in knee 
joint regeneration has investigated the use of a thermally 
responsive ELR that could spontaneously aggregate upon 
injection to form a “drug depot”. The in vivo biodistribution 
in a rat model showed that the aggregated ELR had an 
approximately 25-fold increase in intra-articular half-life in 
comparison with the non-aggregated ELR. This finding 
made it appropriate for sustained delivery of protein drugs 
for treating osteoarthritis [99]. More recent work in the 
treatment of post-traumatic arthritis involved the 
development of a cross-linked ELR and the evaluation of 
intra-articular delivery of IL1Ra (IL1 receptor antagonist) 
and TNFRII (TNFα inhibitor). The results showed a 
sustained delivery of both inhibitors and a corresponding 
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decrease in osteoarthritic damage caused by the disease 
[100]. As regards the development of carriers for the 
delivery of osteogenic drugs, such as bone morphogenetic 
protein (BMP)-2 and BMP-14, a VPAVG-based ELR that 
forms stable and monodisperse depots was used to 
encapsulate both therapeutic proteins separately. The in vitro 
release profile was found to be fast during the first 24 hours 
followed by a slower release over 14 days. Trans-
differentiation of C2C12 mouse myoblast cells towards 
osteoblasts in in vitro cell culture experiments demonstrated 
the efficient delivery of both BMPs. These results suggest 
the application of this system in the delivery of many other 
drugs [101]. 
ELR depots can also be applied in other pathological targets 
such as neuroinflammation in order to improve the 
inflammatory symptoms. In studies to treat local 
neuroinflamation at the dorsal root ganglion using ELR 
depots, a sevenfold increase was found in perineural half-life 
in comparison with the soluble ELP. This result provides 
evidence of high and sustained levels of therapeutics at the 
dorsal root ganglion while minimizing systemic exposure 
[102]. Another interesting approach in the growing field of 
neuroinflamation is the use of depots comprising ELRs 
chemically conjugated to curcumin (a TNFα antagonist) via 
a degradable carbamate linkage [103]. The resulting ELR 
maintained the thermally-triggered depot formation after 
curcumin conjugation and hence the bioactivity against 
TNFα. When injected proximal to the sciatic nerve in mice 
via intramuscular (i.m.) injection, ELR-curcumin underwent 
a thermally triggered soluble-insoluble phase transition, thus 
leading to in situ formation of a depot and resulting in a 
fivefold higher level of the drug at four days post-injection 
when compared with the free drug and an up to sevenfold 
decrease in plasma levels. 
ELR-radionuclide conjugates have been explored as therapy 
for the local treatment of tumours. In this case, an ELR was 
designed and conjugated to the therapeutic agent iodine-131 
and delivered intratumourally. An increase in the residence 
time in the tumour, together with a longer protection of the 
radionuclide from halogenation, when compared with a 
soluble ELR, was observed [104]. Although these ELR-
iodine-131 depots improved survival and tumour regression 
in murine xenograft tumours, they were unable to achieve 
complete tumour regression. Further optimization was 
performed to improve this aspect [105]. This optimization 
was achieved after investigating the effect of a wide range of 
parameters that influence tumour retention and modulate the 
physical properties of the depot, such as molecular weight, 
amino-acid composition and the tyrosine-rich peptide 
appended to the carboxy-terminus for radiolabelling. The 
radionuclide-polypeptide resulting from this study was able 
to self-assemble to form seeds that led to prolonged 
intratumoural retention, tumour growth delay in 100% of 
tumours and cure in more than 67% of tumour-bearing 
animals in two human xenografts of hypopharyngeal and 
prostate cancer cells (FaDu and PC-3 respectively). 
ELR depots can also be used to deliver the glucagon-like 
peptide-1 (GLP-1), with which they form a 50 kDa polymer 
that has shown great promise for the treatment of type 2 
diabetes with a glucose-dependent insulinotropic effect. 
Following this strategy, ELR depots were genetically 
designed with the incorporation of GLP-1 flanked by 
protease cleavage sites [106]. The delivery of GLP1 from the 
depot and activation of the GLP-1 receptor were 
subsequently confirmed. The resulting depot was termed a 
“protease operated depot” (POD). The novel contribution of 
this system lies in the reduction in the number of injections 
since a single injection of GLP1-ELR depot reduced blood 
glucose levels in mice for up to 5 days, which is 120 times 
longer than for an injection of the native peptide. 
Different ELRs hydrogels have been designed for 
biomedical applications with an amphiphilic block co-
recombinamer structure that spontaneously self-assemble to 
form gels which physical crosslinking relying on 
hydrophobic interactions between apolar blocks. These 
systems mimick in vivo cellular environment enabling in 
vitro studies of cell-ECM interactions [107]. Being made up 
of ELRs constitutes and advantage because of their tunable 
mechanical properties,  well defined biological and chemical 
activity and, if necessary, a controlled topography [108, 
109]. These features made them potentially useful  as 
scaffolds for tissue engineering. The only drawback with 
such non-covalent bonding is that it sometimes results in 
inadequate mechanical properties or low stability of these 
structures. To overcome these disadvantages and to stabilize 
ELR-based hydrogels, a bioinspired peptide such as the silk 
fibroin domain [110], which is able to establish more robust 
physical cross-links, has been incorporated into the ELR 
backbone to give rise to the family of silk-elastin-like 
polymers (SELPs). This family of genetically engineered 
protein block copolymers is made up of silk fibroin domains, 
which follow patterns such as GAGAGS, and elastin-like 
blocks of the type GXGVP, where the guest amino acid “X” 
can be any amino acid except proline. The silk-like block 
tends to self-assemble into an anti-parallel β-sheets 
secondary structure, thereby providing physical crosslinking 
sites for the SELP polymeric systems that enable access to 
physical hydrogels with higher thermal and chemical 
stability and mechanical tunability [111]. Exhaustive studies 
have been conducted into the modulation of SELP 
properties, especially by varying the silk-elastin ratio [112], 
molecular weight [113] and X residue in the elastin sequence 
[114]. SELPs can act as an injectable gel-forming material 
for controlled drug and gene release of DNA under 
physiological conditions. Initial research by Gustafson et al. 
[112] studied the release from hydrogels comprising various 
SELPs with different silk-elastin ratios and loaded with 
adenoviruses carrying reporter genes for head and neck 
tumours. The biopolymer SELP-815K, with eight silk and 
fifteen elastin units and a lysine (K)-modified elastin, had the 
highest ratio of silk content and showed the highest gene 
expression compared with the others studied (SELP-415K 
and SELP-47K). The tumour to liver expression ratio was up 
to 55-fold higher for the SELP-815K system compared to 
viral injection without the polymer, thus proving the utility 
of these matrices for gene therapy in head and neck cancer. 
Subsequent studies [115] with SELR matrices consisting of 
the same structured SELP (SELP-815K) loaded with an 
adenovirus containing both thymidine kinase-1 and 
luciferase genes was performed to check the efficacy and 
safety of tumour therapy. The SELP-815K delivery system 
was injected intratumourally into a mouse model of head and 
neck cancer and the gene transfection efficiency, duration of 
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transgene expression and biodistribution analyzed using the 
bioluminescence provided by the luciferase gene. SELP-
controlled therapeutic agent delivery at the tumour site 
resulted in greater confinement, with no detectable spread to 
the liver, which contrasts with the results obtained for intra-
tumoural injection of adenoviruses in saline, in which 50% 
of animals showed clear liver dissemination. An 
approximately fivefold greater reduction in tumour size was 
observed in the adenovirus-SELP 815K system compared 
with the results obtained for saline/adenovirus treatment, 
thus demonstrating the anticancer efficacy of these hydrogel 
systems [115]. 
SELP structures modified to introduce sensitivity to matrix-
metalloproteinases (MMPs) were designed to increase the 
local delivery of bioactive agents to solid tumours in which 
MMPs are overexpressed. A hydrogel that is degradable by 
MMPs was produced and its protease sensitivity tested in 
vitro by incubation with different metalloproteinases (MMP-
2 and MMP-9) to assess complete removal from the potential 
administration site and the correct release of bioactive 
agents. This was checked by measuring the mechanical 
properties of the hydrogel and the fluorescence of 
polystyrene beads released, with the results suggesting the 
ability of these systems to respond to local changes in MMP 
concentration when injected intratumourally [116]. In vivo 
degradation assays were subsequently performed in the 
presence of solid head and neck tumours. A significantly 
higher degradation was observed for MMP-responsive 
SELPs than for SELP-815K, whereas degradation of their 
hydrogel devices is polymer structure dependent, thus 
demonstrating the tunable nature of MMP-responsive SELPs 
for matrix-mediated gene delivery [117]. In light of the 
above, we can conclude that this type of biomaterial is 
especially useful for gene therapy as polymeric hydrogels 
control DNA release, allow localized delivery to specific or 
damaged tissue and protect DNA from degradation, thereby 
improving the safety and efficacy of gene delivery. 
ELRs have been used to form ELR-collagen hydrogels in 
order to optimize and reinforce the features of pure collagen 
hydrogels. One of the most widely applied hydrogels for 
local drug delivery applications is that comprising collagen, 
despite the fact that it lacks the rigidity required for tissue 
engineering and, more importantly, that it is rapidly 
degraded by collagenases to form products that elicit 
inflammation. Anderson and co-workers have prepared ELP-
collagen hydrogels physically cross-linked by hydrogen 
bonding and hydrophobic associations that displayed 
superior physical and mechanical properties than pure 
collagen scaffolds, which was attributed to a homogeneous 
network structure with additional reinforcement due to the 
ELR aggregates [118]. Subsequent studies concerned the 
release behaviour of the ELR-collagen hydrogels prepared in 
the presence of doxycycline hyclate and loaded with 
different amounts (1-5%, w/w) of this commonly used 
broad-spectrum antibiotic in periodontal or acne therapy. 
The ELR-collagen composite showed slower doxycycline 
release compared to the collagen hydrogels, probably due to 
a smaller swelling ratio, with a gradual time-dependent drug 
release over a period of 5 days irrespective of the hydrogel 
composition. The collagen and ELR that make up the 
hydrogels did not interfere with the bioactivity of the drug 
and the released doxycycline was effective against four 
bacterial strains (E. coli, P. aeruginosa, S. sanguinis and 
methicillin-resistant Staphylococcus aureus), thus meaning 
that this biocompatible composite hydrogel allows sustained 
release of an antibiotic at the local site with the potential to 
minimize post-surgical infections and support wound 
healing. 
A novel ultrasound-based method has been used to generate 
physical ELR hydrogel scaffolds for the local delivery of 
proteins and antibiotics. These hydrogels are formed by 
sonicating an aqueous solution of the recombinamer 
[(VPGVG)120] for a short period of time at low temperature 
(4°C) and subsequently incubating at physiological 
temperature for an extended period of time, in the presence 
of bovine serum albumin and doxycycline hyclate, which 
were added to the sonicated ELR to be enclosed. The 
mechanism suggested for physical cross-linking involves a 
hydrophobic interaction between polymeric chains after 
ultrasonication. The release of BSA and doxycycline from 
the scaffold was studied at different temperatures, above (37 
°C) and below (25 °C) the transition temperature (Tt) and 
with different loading concentrations of both bioactive 
molecules. Both BSA and doxycycline showed a gradual 
time-dependent release that is affected by factors such as 
drug molecular weight and loading concentration. The 
highlight of this approach is the ease of formation of ELR 
hydrogels without needing to add chemical crosslinking 
agents and a release governed by different factors such as 
temperature or drug loading dose, thereby suggesting 
potential applications in controlled drug delivery [119]. 
To increase the structural stability and mechanical properties 
of ELR hydrogels, which may be necessary for some 
applications, chemical hydrogels were synthesised by 
chemical, enzymatic or photo-irradiated cross-linking [120-
123]. In addition, a chemical hydrogel to be used as an 
injectable “click” system has been developed starting from a 
pair of elastin-like recombinamers suitably chemically 
modified in such a way that a covalently crosslinked 
hydrogel is formed under physiological conditions, in a short 
period of time, and once the two components are in contact. 
The inclusion of an amino acid that can subsequently be 
modified to contain adequate functional groups for covalent 
cross-linking is necessary for this purpose. The introduction 
of a lysine residue as a guest amino acid distributed along 
the peptide chain allows ELRs to be modified at the ɛ-amino 
group to bear the reactive groups necessary for the “click 
reaction” [11].  To this end, ELRs were modified to carry 
azide and cyclooctyne groups capable of generating 
interchain bonds through triazol heterocycles via a copper-
free 1,3-dipolar cycloaddition. The resulting hydrogel system 
is biocompatible and permits the homogeneous entrapment 
of drugs and bioactive molecules [124]. Nanogels were 
prepared at different temperatures by mixing dilute solutions 
of the aforementioned click-reactive ELRs with the aim of 
understanding the relation between the macroscopic 
properties of the resulting ELR-click gels and the initial 
stages of the chemical crosslinking process, which involve 
fractal modes of gel formation. Different topographies were 
obtained for the nanogels prepared at temperatures below 
and above the molecular transition temperature of the ELRs, 
thus implying that the cross-linking temperature determines 
the microstructure of the final hydrogels [124]. In a 
subsequent study, the previously developed hydrogels 
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obtained by the catalyst-free click reaction of elastin-like 
recombinamers were used to fabricate a new class of 
vascular stents coated with this biocompatible material. 
Thus, the bare metal stent is embedded into an injection 
mold that is filled with the ELR gel. In order to avoid 
atherosclerotic plaque formation that induces re-stenosis, 
stent endothelization was performed in a bioreactor under 
dynamic pressure and flow conditions. Once endothelialized, 
the ELR-covered stents constituted an endovascular device 
with a physical barrier against atherosclerotic plaque, 
biocompatibility, no inflammatory response and 
physiological haemocompatiblity, thus paving the way to a 
future generation of eluting stents [125]. 
One of the most advanced hydrogel-based constructs for 
drug delivery is made up of enzymatically cross-linked ELRs 
that are able to release bioactive substances under specific 
stimulus from the environment. As has been described 
previously [126], there is a correlation between the 
elastolytic activity and pathological conditions such as 
atherosclerosis, cystic fibrosis or chronic wounds, amongst 
others. In this regard, Bandiera et al. have designed an ad 
hoc ELR-based hydrogel system that carries both chemical 
cross-linking and protease-sensitive domains (Figure 5). 
ELR crosslinking is performed via transglutaminases in the 
presence of a recombinant green fluorescent protein (eGFP) 
that is embedded during the gelation process. The hydrogels 
formed were exposed to the proteolytic activity derived from 
P. aeruginosa and human polymorphonuclear leukocytes 
(PMNs), which triggered the gradual release of eGFP from 
the matrix as it was degraded. In short, a drug delivery 
platform capable of interacting with biological systems that 
can sense a chemical abnormality in damaged tissues and 
respond by releasing the therapeutic agent to interfere with 
the pathological process, thus leading to the inhibition of 
potentially harmful processes, has been designed [127]. 
Figure 5. Bioactive molecule delivery triggered by 
elastolytic activity of pathological processes and drug release 
leading to proteolytic activity inhibition. Adapted with 
permission from Bandiera et al. [127]. 
An alternative approach to chemical hydrogels is that 
designed by Chilkoti et al., which consists of a reversible 
hydrogel that is formed under mild oxidative conditions by 
intermolecular disulfide chemical crosslinking of ELRs 
containing periodic cysteine residues along their chain. The 
rapid gelation of these custom-designed ELRs under 
physiological conditions upon addition of a low 
concentration of hydrogen peroxide (0.3 wt %) makes them 
useful as an injectable gel-forming material. Preliminary in 
vitro studies of the release profiles for BSA protein indicated 
a sustained release pattern, thereby demonstrating the 
advantage of hydrogel formation for stable entrapment of a 
BSA payload with respect to the control ELR-based 
coacervates. Indeed, after 4 hours of incubation only 20-40% 
of release was detected for ELR hydrogels crosslinked via 
cysteine residues, whereas complete release was observed 
for ELR coacervates over the same time period. The in vivo 
intratumoural injection of in situ gelling radiolabelled ELR 
to mice bearing human pharynx squamous xenografts 
showed higher and more prolonged tumour retention (greater 
than 40% of the payload) and homogeneous distribution 
across the entire tumour, in contrast to ELR coacervates, for 
which retention was less than 10%. This enhancement of 
radionuclide retention makes these systems suitable for local 
cancer therapy of tumours refractory to surgical removal. 
5. SMART DRUG-DELIVERY SYSTEMS NOT 
INVOLVING ELRS 
Numerous drug-delivery systems other than those based on 
elastin have been designed to achieve therapeutic efficiency 
at the application site and to overcome the aforementioned 
limitations in classical therapeutic disease treatments [2]. 
The most common such drug-delivery systems comprise new 
macromolecular carriers with a defined structure and 
properties that can respond to environmental stimuli with a 
pronounced change in their structure. To the best of our 
knowledge, these drug-delivery systems can be made from a 
wide variety of structures involving both polymeric and non-
polymeric building blocks [32]. One interesting 
improvement is the use of environmentally sensitive 
polymers that are able to respond to external stimuli such as 
temperature, pH, ion concentration or electric fields, among 
others. A great variety of drug-delivery vectors have been 
designed using the above-mentioned building blocks, 
including micelles, liposomes, polymeric and protein drug 
conjugates or inorganic nanoparticles, each with different 
advantages [3, 4, 128]. 
Amongst other polymeric drug-delivery systems consisting 
of natural proteins, those based on silk and collagen, which 
have been mentioned above in combination with ELPs, can 
be highlighted. 
Silk proteins has been used with great success in devices for 
cell culture and tissue regeneration and have been approved 
by the FDA due to their versatility and biocompatibility 
[129, 130]. Numata et al. have proposed a genetically 
engineered silk-based ionic pDNA complex with a poly(L-
lysine) that interacts with pDNA and has a higher content of 
tumour-homing peptide (THP) than in their previous studies 
in this field with the aim of improving its transfection 
efficiency and specificity for tumour cells [131]. Two 
different THPs were used with three different cell lines, 
namely MDA-MB-435 melanoma, MDA-MB-231 metastatic 
human breast tumour cells and MCF10A non-tumour 
mammary epithelial cells as control. The results showed that 
the pDNA complexes containing THP showed greater 
specificity against tumour cells compared with lipofectamine 
and the pDNA complex without THP used as control. In 
addition, a comparison of these THPs showed that the pDNA 
complex with F3 as THP appears to be the best candidate for 
target delivery due to its lower cytotoxicity as a result of the 
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ability of pDNA to complex with Lyp1 to transfect non-
tumourigenic cells [132]. 
A very recent study describes the fabrication of silk fibroin 
(SF) microparticles for the delivery of small-molecule drugs 
for the treatment of arthritis by increasing the local residence 
time after intra-articular injection of the drug-loaded 
particles. To this end, microparticles were formed from a 
solution of a mixture of SF and the fluorophore Cy7, which 
establish mutual hydrophobic interactions, using previously 
described methods but with different ratios of the two 
components. Microparticle formation was confirmed by 
scanning electron microscopy, finding a wide range of 
particles that were nevertheless suitable for intra-articular 
injection. In vitro release studies revealed a faster release in 
the case of particles containing lower amounts of SF, thereby 
suggesting a negative effect of Cy7 on particle stabilization 
by diminishing intermolecular SF interactions. However, the 
release of Cy7 exceeded 10% of the loaded molecule over 
the 160 h that the experiment lasted. Additional experiments 
were performed in rats to evaluate intra-articular retention of 
the fluorophore using an in vivo imaging instrument. 
However, as Cy7 scattering and decay resulted in difficulties 
in measuring the evolution of the model compound over 
space and time, the decay half-life was used as the study 
parameter and showed an increase from 12.6 h (±2.2 h), in 
the case of the SF-Cy7 solution without particle-forming 
treatment to 43.3 h (±14.4 h) for the SF-Cy7 microparticles. 
Moreover, localization was improved with the novel 
treatment, thereby reducing the exposure of adjacent tissues 
to the fluorophore. All these findings suggest the need for 
further studies regarding this approach to intra-articular 
drug-delivery systems [133]. However, some problems arise 
from this work as the particles were not loaded with an 
actual drug or with non-hydrophobic molecules. 
Furthermore, fluorophore decay half-life might not be an 
accurate measurement of drug retention, although a slower 
decay was demonstrated when compared to SF-Cy7 
solutions. 
Collagen can be shaped into a great variety of forms for use 
as scaffolds or drug-delivery systems in numerous medical 
applications [134]. In order to prepare novel collagen (CG) 
scaffolds for use as drug-delivery systems that are likely to 
respond to an external stimulus, they were loaded with 
paramagnetic iron oxide nanoparticles (NPs) and 
subsequently covalently cross-linked by way of a 
dehydrothermal cross-linking treatment to obtain porous 
matrices. Different characterization techniques were used to 
gain information about the scaffolds themselves (e.g. SEM) 
and the amount of NPs included in them (thermogravimetric 
analysis). Fluorescein was subsequently used as a model 
compound to study the release by fluorescence spectrometry. 
The results showed a very low diffusion of fluorescein after 
immersion of the CGNP scaffold in water during 60 minutes 
when compared to the CG control. Furthermore, a controlled 
release of the compound was observed upon application of 
an external magnetic field to the NP-loaded system, and said 
release could be switched on and off by switching the 
magnetic field on and off. Finally, a cell viability assay was 
performed with the scaffold alone. This study showed a 
reduction of about 10% in cell survival in the case of both 
CG and CGNPs when compared to the negative control, 
which could be considered as a promising result for further 
application of this system [134]. 
As regards polymeric carriers for encapsulated drugs, 
numerous types of synthetic materials are currently 
employed, including poly(lactic acid) (PLA), poly(ɛ-
caprolactone) (PCL), and poly(lactide-co-glycolide) (PLGA) 
[4]. Indeed, poly(lactic-co-glycolic acid) (PLGA) has been 
approved by the FDA for use in several therapeutic devices 
because of its ability to biodegrade, its biocompatibility and 
its multi-responsive behaviour [35, 135]. PLGA has found 
numerous applications, for example, in tissue engineering, 
medical and surgical devices and drug delivery [35]. Herein 
we focus our attention on applications of importance in drug 
delivery. Thus, numerous chemotherapeutic agents, such as 
docetaxel, paclitaxel, doxorubicin and other peptides, can be 
delivered using PLGA-based delivery systems [35]. 
Moreover, PLGA inmunoconjugates can be applied as 
targeted anti-cancer systems. Thus, Parveen et al. designed a 
PLGA-chitosan-PEG (polyethylene glycol) conjugated with 
paclitaxel, and in vitro studies carried out in retinoblastoma, 
invasive breast cancer and pancreatic cell lines demonstrated 
that PLGA-CS-PEG nanoparticles have a more potent 
antiproliferative effect and ability to induce cell cycle arrest 
than PLGA nanoparticles and free paclitaxel. These results 
suggest that the new conjugate with PEG and chitosan could 
be a future candidate for targeted delivery of 
chemotherapeutic agents [136]. Another targeted delivery 
system could be applied in the field of diagnostic imaging, as 
proposed by Niu et al. and Schleich et al. in recent studies 
[137, 138]. 
Collagen membranes are excellent candidates for guided 
bone regeneration (GBR) in combination with bone grafting 
materials (BGM) as they are subsequently absorbed, thereby 
avoiding the need for second surgery to remove the 
membrane [139]. However, as mentioned earlier, this system 
undergoes fast degradation, thereby limiting the possibility 
of the controlled release of drugs such as dexamethasone 
(DEX), which is an excellent osteoinductive growth factor 
[140-143]. Piao et al. have overcome this problem by 
incorporating PLGA, which is an excellent controlled release 
carrier that allows an efficient release of the drug [144, 145]. 
In vitro studies in MG63 cells revealed that release of DEX 
from PLGA on the collagen surface is faster by day 5 but can 
be controlled for four weeks. These results also show that 
PLGA improves the attachment of cells in the collagen 
membrane conjugate compared with the collagen membrane 
also. In vivo analyses have been carried out in rat models 
with a calvarial bone defect. The results obtained after eight 
weeks showed that the collagen membrane coated with has a 
better ability to induce osteogenesis than the membrane 
without DEX [146] due to controlled release from PLGA 
into the collagen membrane. DEX induces cell proliferation, 
differentiation, extracellular matrix secretion and tissue 
formation [147]. 
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A new approach, namely the use of PLGA as a coating for 
drug-eluting stents, has recently been gaining importance, 
especially as atherosclerosis is one of the main problems 
related to stent implantation. In initial studies, Ganaha et al. 
had shown the ability of a combination of PLGA 
microspheres with a stainless steel stent and angiostatin to 
decrease plaque progression and avoid re-stenosis [148]. The 
favourable characteristics of PLGA, such as 
biocompatibility, biodegradability and its non-toxic 
properties, offer a wide range of possibilities for application 
in the development of new drug-delivery systems and other 
biomedical applications. 
A novel proposal for the treatment of invasive breast cancer, 
consisting of a pH-sensitive polymer conjugated with siRNA 
fragments, was developed by Kaushal et al. This system 
comprises a β-cyclodextrin core linked to the designer 
polymer by an acid-labile hydrazone bond, with the polymer 
itself comprising a hydrophobic monomer (HMA, 
hydrophobic hexyl methacrylate) connected to a pH-
sensitive monomer (DMAEMA, 2-(dimethylamino)ethyl 
methacrylate) and, in turn, to a cationic monomer 
(TMAEMA, N,N,N-trimethylaminoethyl methacrylate) 
(Figure 6). This latter cationic domain is attached to the 
antiRhoC siRNA by electrostatic interactions between the 
amine groups of the polymer and the phosphate groups of the 
siRNA. In vivo studies in SUM149 and MDA-MB-231 cell 
lines revealed that the resulting nanoparticles can be 
internalized into the cells, then leak from the endosome to 
subsequently deliver their siRNA load. Expression of the 
RhoC gene is selectively diminished by 90-100% and, as a 
result, the invasion, motility and migration of both SUM149 
and MDA-MB-231 are considerably reduced. Other targets 
could be explored in the future with the aim of increasing the 
diversity of these smart nanoparticles combined with siRNA 
to reduce cell invasion and motility and induce an ability to 
reduce other types of tumour cells [149]. 
Other non-polymeric drug-delivery carriers are defined by 
non-repetitive amino acid motifs with an ability to form 
tertiary or quaternary structures, including vault proteins [33] 
and viral proteins, amongst other [34]. 
One example of vault proteins was proposed by Buehler et 
al. with the aim of improving their previous proposals for 
vault-drug delivery [33]. In this case, they formed a new 
class of nanoparticles resulting from the covalent attachment 
of NS5A1-31amphipathic α-helix (a peptide derived from 
hepatitis C virus) to MVP, with these NPs showing a self-
assembled protein shell with a lipophilic core that is able to 
retain small molecules for subsequent controlled drug 
delivery. Bryostatin 1 was subsequently incorporated into the 
AH-vault carrier with the aim of developing an anti-
HIV/AIDS agent. Previous studies showed that bryostatin 1 
incorporated into lipid nanoparticles can activate latent HIV 
and can be triggered against CD4+ T cells [150]. The 
resulting AH-vault-bryostatin 1 was found to activate latent 
HIV provirus in J-Lat 10.6 cells in a dose-dependent manner 
compared with empty AH-vaults, and was also able to 
prompt cell-surface expression of CD69 at similar 
concentrations to those required to activate latent HIV [151, 
152]. In vivo analyses in C57/bl6 mice revealed that over 
90% of CD4+ had been induced to express CD69 24 h post-
injection of AH vault with bryostatin 1, thus highlighting  
Figure 6. (A) Chemical structure of the pH-sensitive, β-CD-
g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 
polymer. (B) Schematic design showing condensation of 
anti-RhoC siRNA molecules by star-shaped pH sensitive 
polymers forming smart particles, which are internalized by 
endocytosis. In the endosome, acid-labile hydrazone linkages 
are hydrolyzed by the acidic pH, which release the P(HMA-
co-DMAEMA-co-TMAEMA) grafts that rupture the 
endosomal membrane and release the loaded siRNA cargo 
into the cytoplasm. In the cytoplasm, anti-RhoC siRNA 
binds to RhoC mRNA triggering its degradation while 
particle debris is eliminated by exocytosis. Reproduced with 
permission from Kaushal et al. [149]. 
that excellent delivery of the drug can be obtained by 
combining both compounds. 
Viral protein nanoparticles (VNPs) are another novel 
strategy for using non-polymeric nanocarriers as a drug-
delivery system due to their excellent ability to mimic the 
natural process by which viruses penetrate cell membranes, 
with the added advantage that these nanoparticles are 
biocompatible and biodegradable. VNPs based on plant 
viruses and bacteriophages are excellent candidates as these 
viral proteins are not able to infect mammalian cells [153-
155]. 
The use of one of these plant viruses for drug delivery has 
been evaluated by Aljabali et al., who showed the ability of 
Cowpea mosaic virus (CPMV) to covalently conjugate with 
DOX in two ways, namely via a stabile amide bond (CPMV-
DOX) and a labile disulfide bridge (CPMV-SS-DOX). In 
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vitro analyses in the HeLa cell line revealed that, at low 
dosage, CPMV-DOX is more effective for cell killing than 
free DOX because of its concentration-independent and 
time-delayed release. CPMV-DOX targets the 
endolysosomal compartment of HeLa cells and reduces the 
side effects of free DOX, such as the cardiotoxicity 
mentioned previously. The results for CPMV-SS-DOX 
revealed that this system exhibits a similar behaviour to 
DOX, possibly due to a more rapid dissociation of the 
disulfide-bridge, and therefore DOX delivery, prior to 
cellular uptake. 
A further application of virus plant nanoparticles has been 
proposed by Esfandiari et al. Thus, a nanoparticle 
comprising potato virus X was conjugated with herceptin, a 
monoclonal anti-Her2/neu antibody that is used as a 
chemotherapeutic agent in breast cancer, via a chemical 
linker. In vitro flow cytometric studies in the SK-BR-3 and 
SK-OV-3 cell lines showed that, at different doses, PVX-
Her2 showed a greater apoptotic effect than the same doses 
of free herceptin [156]. 
Metal organic frameworks (MOFs) comprise a combination 
of metals connected to organic molecules via a linker. These 
systems are attracting increasing interest in biomedical 
applications due to their excellent ability to encapsulate and 
protect the drug release, thus making them good systems for 
drug delivery [157]. In order to demonstrate the controlled 
delivery of drugs by such systems, Adhikari et al. designed a 
pH-responsive zeolitic imidazole framework (ZIF) 
containing zinc as the metal component and imizadole or 
another derivative as organic linker [158] with aim of 
encapsulating DOX within two different ZIFs. The resulting 
polymers showed an enormous difference in terms of their 
pH-responsiveness, with ZIF-8 demonstrating an efficient 
response capacity at acidic pH, releasing DOX in the 
required manner. However, in the presence of liposomes and 
micelles, both ZIFs exhibited a high release rate, especially 
ZIF-8, probably due to the destabilization of their respective 
structures. The authors of this study demonstrated that drug 
release can be controlled without difficulty using different 
ZIFs and, optionally, liposomes [159]. 
CONCLUSION 
ELRs have been extensively used for drug delivery in a 
variety of different forms, including soluble macromolecular 
carriers, self-assembled nanoparticles, cross-linked 
microparticles, thermally coacervated depots or crosslinked 
hydrogels. Targeted drug delivery using soluble 
macromolecular carriers encompasses different constructs, 
such as ELR-drug recombinant fusion constructs, ELR-drug 
systems chemically bioconjugated in their monomeric and 
soluble form, and drug encapsulation by nanoparticle-
forming ELRs. These constructs allow controlled release at 
the target site, thereby suggesting the potential of elastin-like 
recombinamers as safe drug carriers for use in the treatment 
of different diseases. 
The reversible phase transition that ELRs undergo in 
response to changes in temperature allows the formation of 
structure-dependent architectures, such as aggregates or 
well-defined nanoparticles, and the use of such systems in 
the biomedical field, especially for drug-delivery purposes 
and even for direct cellular uptake. Particularly interesting 
examples of this can be found in cancer treatment, where the 
use of local mild hyperthermia and enhanced permeability 
retention has resulted in satisfactory treatments targeted 
directly at the tumour site. 
The direct application of ELRs by injection as soluble 
monomers at the site of action to form depots extends drug 
exposure time while minimizing systemic side effects. This 
also paves the way to advanced medical applications, such as 
in tissue regeneration, neuroinflammation, cancer and 
diabetes. In addition, the use of ELR-based hydrogel systems 
that act as both a support and reservoir in which drugs can be 
stored results in a non-fluctuating and sustained drug release, 
thereby reducing side effects and increasing drug retention at 
the site of action with respect to the administration of free 
drugs. 
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